keyword
MENU ▼
Read by QxMD icon Read
search

Royal marsden

keyword
https://www.readbyqxmd.com/read/28319327/bilateral-breast-reconstruction-with-deep-inferior-epigastric-perforator-flaps-in-slim-patients
#1
Maria Mani, Samer Saour, Kelvin Ramsey, Kieran Power, Paul Harris, Stuart James
BACKGROUND: Slim women are not always considered candidates for bilateral autologous breast reconstruction. The study aims to assess the volume considerations and complications of deep inferior epigastric perforator (DIEP) flap in bilateral breast reconstruction among slim patients. METHODS: All patients undergoing bilateral DIEP breast reconstruction at the Royal Marsden Hospital, London, September 2007-March 2015, were reviewed. Flap weight was compared to mastectomy weight (weight ratio) and complications were recorded...
March 20, 2017: Microsurgery
https://www.readbyqxmd.com/read/28273485/clinical-factors-of-response-in-patients-with-advanced-ovarian-cancer-participating-in-early-phase-clinical-trials
#2
Angela George, Rebecca Kristeleit, Saeed Rafii, Caroline O Michie, Rebecca Bowen, Vasiliki Michalarea, Tom van Hagen, Mabel Wong, Grigorios Rallis, L Rhoda Molife, Juanita Lopez, Udai Banerji, Susana N Banerjee, Martin E Gore, Johann S de Bono, Stan B Kaye, Timothy A Yap
Drug resistance to conventional anticancer therapies is almost inevitable in patients with advanced ovarian cancer (AOC), limiting their available treatment options. Novel phase I trial therapies within a dedicated drug development unit may represent a viable alternative; however, there is currently little evidence for patient outcomes in such patients. To address this, we undertook a retrospective review of patients with AOC allocated to phase I trials in the Drug Development Unit at Royal Marsden Hospital (RMH) between June 1998 and October 2010...
March 5, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28246081/the-4ps-of-breast-cancer-chemoprevention-putting-proven-principles-into-practice
#3
EDITORIAL
V Craig Jordan
The pioneering Royal Marsden Tamoxifen Prevention Trial recruited 2,471 eligible high-risk women to be randomized to either placebo or tamoxifen (20 mg daily) for 8 years. Breast cancer incidence was evaluated at a median of 18.4 years from the start of the study. There was a 32% reduction in estrogen/progesterone receptor (ER/PR)-positive breast cancers after tamoxifen treatment finished. Translational research, to study "the good, the bad, and the ugly of tamoxifen" in the 1980s, subsequently ensured women's safety from possible increases in osteoperosis, coronary heart disease, and endometrial cancer...
February 28, 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/28214659/clinical-outcomes-and-prognostic-factors-of-patients-with-advanced-mesothelioma-treated-in-a-phase-i-clinical-trials-unit
#4
Dionysis Papadatos-Pastos, Desam Roda, Maria Jose De Miguel Luken, Ann Petruckevitch, Awais Jalil, Marta Capelan, Vasiliki Michalarea, Joao Lima, Nikolaos Diamantis, Jaishree Bhosle, L Rhoda Molife, Udai Banerji, Johann S de Bono, Sanjay Popat, Mary E R O'Brien, Timothy A Yap
BACKGROUND: We have previously reported a prognostic score for patients in phase I trials in the Drug Development Unit, treated at the Royal Marsden Hospital (RPS). The RPS is an objective tool used in patient selection for phase I trials based on albumin, number of disease sites and LDH. Patients with mesothelioma are often selected for phase I trials as the disease remains localised for long periods of time. We have now reviewed the clinical outcomes of patients with relapsed malignant mesothelioma (MM) and propose a specific mesothelioma prognostic score (m-RPS) that can help identify patients who are most likely to benefit from early referral...
February 16, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28110982/diagnostic-accuracy-of-multi-parametric-mri-and-trus-biopsy-in-prostate-cancer-promis-a-paired-validating-confirmatory-study
#5
Hashim U Ahmed, Ahmed El-Shater Bosaily, Louise C Brown, Rhian Gabe, Richard Kaplan, Mahesh K Parmar, Yolanda Collaco-Moraes, Katie Ward, Richard G Hindley, Alex Freeman, Alex P Kirkham, Robert Oldroyd, Chris Parker, Mark Emberton
BACKGROUND: Men with high serum prostate specific antigen usually undergo transrectal ultrasound-guided prostate biopsy (TRUS-biopsy). TRUS-biopsy can cause side-effects including bleeding, pain, and infection. Multi-parametric magnetic resonance imaging (MP-MRI) used as a triage test might allow men to avoid unnecessary TRUS-biopsy and improve diagnostic accuracy. METHODS: We did this multicentre, paired-cohort, confirmatory study to test diagnostic accuracy of MP-MRI and TRUS-biopsy against a reference test (template prostate mapping biopsy [TPM-biopsy])...
February 25, 2017: Lancet
https://www.readbyqxmd.com/read/28100469/immunohistochemical-phenotype-of-breast-cancer-during-25-year-follow-up-of-the-royal-marsden-tamoxifen-prevention-trial
#6
Simone I Detre, Susan Ashley, Kabir Mohammed, Ian E Smith, Trevor J Powles, Mitch Dowsett
The randomized, double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. Eligible participants (n = 2,471) were randomly assigned to tamoxifen (20 mg/d) or placebo for 8 years. Analysis in 2006 showed a 30% risk reduction of estrogen receptor (ER)-positive invasive breast cancer mostly in the posttreatment period. Biomarker analysis in this population may identify any subgroup-specific preventive effects tamoxifen. After a median follow-up of 18...
January 18, 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/28099210/pazopanib-a-promising-option-for-the-treatment-of-aggressive-fibromatosis
#7
Zoltan Szucs, Christina Messiou, Han Hsi Wong, Helen Hatcher, Aisha Miah, Shane Zaidi, Winette T A van der Graaf, Ian Judson, Robin L Jones, Charlotte Benson
Desmoid tumour/aggressive fibromatosis (DT/AF) is a rare soft-tissue neoplasm that is locally aggressive but does not metastasize. There is no standard systemic treatment for symptomatic patients, although a number of agents are used. Tyrosine kinase inhibitors have recently been reported to show useful activity. We reviewed our bi-institutional (Royal Marsden Hospital, Cambridge University Hospitals) experience with the tyrosine kinase inhibitor pazopanib in the treatment of progressing DT/AF. Eight patients with DT/AF were treated with pazopanib at Royal Marsden Hospital and Cambridge University Hospitals between June 2012 and June 2016...
April 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28048582/th-ab-brb-03-4n-radiotherapy
#8
K Sheng
Current state-of-the art digital C-arm medical linear accelerators are capable of delivering radiation treatments with high level of automation, which affords coordinated motions of gantry, couch, and multileaf collimator (MLC) with dose rate modulations. The new machine capacity has shown the potential to bring substantially improved radiation dosimetry and/or delivery efficiency to many challenging diseases. Combining an integrated beam orientation optimization algorithm with automated machine navigation, markedly improved dose conformity has been achieved using 4ρ therapy...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28047855/th-ab-brb-00-research-opportunities-with-digital-linear-accelerators
#9
Ke Sheng
Current state-of-the art digital C-arm medical linear accelerators are capable of delivering radiation treatments with high level of automation, which affords coordinated motions of gantry, couch, and multileaf collimator (MLC) with dose rate modulations. The new machine capacity has shown the potential to bring substantially improved radiation dosimetry and/or delivery efficiency to many challenging diseases. Combining an integrated beam orientation optimization algorithm with automated machine navigation, markedly improved dose conformity has been achieved using 4ρ therapy...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28047193/th-ab-brb-01-trajectory-modulated-arc-therapy-application-to-partial-breast-irradiation
#10
D Hristov
Current state-of-the art digital C-arm medical linear accelerators are capable of delivering radiation treatments with high level of automation, which affords coordinated motions of gantry, couch, and multileaf collimator (MLC) with dose rate modulations. The new machine capacity has shown the potential to bring substantially improved radiation dosimetry and/or delivery efficiency to many challenging diseases. Combining an integrated beam orientation optimization algorithm with automated machine navigation, markedly improved dose conformity has been achieved using 4ρ therapy...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28047019/th-ab-brb-04-quality-assurance-for-advanced-digital-linac-implementations
#11
V Yu
Current state-of-the art digital C-arm medical linear accelerators are capable of delivering radiation treatments with high level of automation, which affords coordinated motions of gantry, couch, and multileaf collimator (MLC) with dose rate modulations. The new machine capacity has shown the potential to bring substantially improved radiation dosimetry and/or delivery efficiency to many challenging diseases. Combining an integrated beam orientation optimization algorithm with automated machine navigation, markedly improved dose conformity has been achieved using 4ρ therapy...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28046523/th-ab-brb-02-et-reloaded
#12
Q Wu
Current state-of-the art digital C-arm medical linear accelerators are capable of delivering radiation treatments with high level of automation, which affords coordinated motions of gantry, couch, and multileaf collimator (MLC) with dose rate modulations. The new machine capacity has shown the potential to bring substantially improved radiation dosimetry and/or delivery efficiency to many challenging diseases. Combining an integrated beam orientation optimization algorithm with automated machine navigation, markedly improved dose conformity has been achieved using 4ρ therapy...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28046362/th-ab-brb-05-using-a-research-real-time-control-interface-to-go-beyond-dynamic-mlc-tracking
#13
S Nill
Current state-of-the art digital C-arm medical linear accelerators are capable of delivering radiation treatments with high level of automation, which affords coordinated motions of gantry, couch, and multileaf collimator (MLC) with dose rate modulations. The new machine capacity has shown the potential to bring substantially improved radiation dosimetry and/or delivery efficiency to many challenging diseases. Combining an integrated beam orientation optimization algorithm with automated machine navigation, markedly improved dose conformity has been achieved using 4ρ therapy...
June 2016: Medical Physics
https://www.readbyqxmd.com/read/28029312/impact-of-a-panel-of-88-single-nucleotide-polymorphisms-on-the-risk-of-breast-cancer-in-high-risk-women-results-from-two-randomized-tamoxifen-prevention-trials
#14
Jack Cuzick, Adam R Brentnall, Corrinne Segal, Helen Byers, Caroline Reuter, Simone Detre, Elena Lopez-Knowles, Ivana Sestak, Anthony Howell, Trevor J Powles, William G Newman, Mitchell Dowsett
Purpose At least 94 common single nucleotide polymorphisms (SNPs) are associated with breast cancer. The extent to which an SNP panel can refine risk in women who receive preventive therapy has not been directly assessed previously. Materials and Methods A risk score on the basis of 88 SNPs (SNP88) was investigated in a nested case-control study of women enrolled in the International Breast Intervention Study (IBIS-I) or the Royal Marsden study. A total of 359 women who developed cancer were matched to 636 controls by age, trial, follow-up time, and treatment arm...
March 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27997738/full-blood-count-internal-qc-protocol-a-review-by-the-royal-college-of-pathologists-of-australasia-quality-assurance-programs-rcpaqap-pty-ltd-haematology
#15
J Sioufi, T Badrick, L Sinclair, K Marsden
INTRODUCTION: The RCPAQAP (Royal College of Pathologists of Australasia Quality Assurance Program) Haematology has undertaken an exercise to review the internal quality control protocol for full blood count (FBC) instrumentation as well as review the action taken by laboratories when nonconforming results are evident in the RCPAQAP proficiency testing reports. METHOD: A questionnaire was sent to laboratories enrolled in the RCPAQAP FBC module. Laboratories were asked to provide information with regard to the type of control measures used within their testing environment that would trigger alerts for nonconforming events...
February 2017: International Journal of Laboratory Hematology
https://www.readbyqxmd.com/read/27981925/comparison-of-presentation-and-outcome-in-100-pediatric-hodgkin-lymphoma-patients-treated-at-children-hospital-lahore-pakistan-and-royal-marsden-hospital-uk
#16
Mahwish Faizan, Mary M Taj, Saadia Anwar, Nyla Asghar, Alia Ahmad, Donna Lancaster, Ayad Atra, Agha Shabbir Ali
OBJECTIVE: To compare differences in demographics and outcomes in childhood Hodgkin lymphoma (HL) presenting at the Children's Hospital Lahore (CHL), and Royal Marsden Hospital (RMH), UK. STUDY DESIGN: An observational comparative study. PLACE AND DURATION OF STUDY: From January 2011 to February 2012 at CH, Lahore and from October 2008 to February 2012 at RMH, UK. METHODOLOGY: Consecutive HL patients (50 from each hospital) were inducted...
November 2016: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/27931133/outcomes-for-transformed-follicular-lymphoma-in-the-rituximab-era-the-royal-marsden-experience-2003-2013
#17
Mary Gleeson, Eliza A Hawkes, Clare Peckitt, Andrew Wotherspoon, Ayoma Attygalle, Bhupinder Sharma, Yong Du, Mark Ethell, Mike Potter, Claire Dearden, Alan Horwich, Ian Chau, David Cunningham
Survival for transformed follicular lymphoma (tFL) has improved in the rituximab era and the need for upfront stem cell transplantation (SCT) is unclear. We evaluated the outcomes for all patients treated with first-line chemotherapy for histologically-proven tFL at our institution from 2003-2013 (n = 87). The majority of patients (89.7%) did not receive a SCT as part of first-line management. With a median follow-up of 7.8 years the 5-year overall survival (OS) for all patients was 61.7%. Patients treated with R-CHOP without upfront SCT (n = 55/87) had a 5-year OS of 64...
August 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27924638/understanding-sarcomas-and-other-rare-tumors-an-interview-with-robin-l-jones
#18
Robin L Jones
Robin L Jones speaks to Jade Parker, Commissioning Editor: Robin Jones is a medical oncologist specializing in the treatment of bone and soft tissue sarcomas and Head of the Sarcoma Unit at The Royal Marsden. He completed his medical training at Guy's and St Thomas' Hospital, and his oncology training at The Royal Marsden. His postgraduate research degree, with Professor Dowsett at the Institute of Cancer Research (ICR), evaluated potential predictive and prognostic factors in breast cancer patients treated with neoadjuvant chemotherapy...
February 2017: Future Oncology
https://www.readbyqxmd.com/read/27662616/prognostic-factors-of-overall-survival-in-children-and-adolescents-enrolled-in-dose-finding-trials-in-europe-an-innovative-therapies-for-children-with-cancer-study
#19
Fernando Carceller, Francisco J Bautista, Irene Jiménez, Raquel Hladun-Álvaro, Cécile Giraud, Luca Bergamaschi, Madhumita Dandapani, Isabelle Aerts, François Doz, Didier Frappaz, Michela Casanova, Bruce Morland, Darren R Hargrave, Lynley V Marshall, Gilles Vassal, Andrew D J Pearson, Birgit Geoerger, Lucas Moreno
OBJECTIVES: Dose-finding trials are fundamental to develop novel drugs for children and adolescents with advanced cancer. It is crucial to maximise individual benefit, whilst ensuring adequate assessment of key study end-points. We assessed prognostic factors of survival in paediatric phase I trials, including two predictive scores validated in adult oncology: the Royal Marsden Hospital (RMH) and the MD Anderson Cancer Center (MDACC) scores. METHODS: Data of patients with solid tumours aged <18 years at enrolment in their first dose-finding trial between 2000 and 2014 at eight centres of the Innovative Therapies for Children with Cancer European consortium were collected...
November 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27602923/magnetic-resonance-tumor-regression-grade-and-residual-mucosal-abnormality-as-predictors-for-pathological-complete-response-in-rectal-cancer-postneoadjuvant-chemoradiotherapy
#20
Jemma Bhoday, Fraser Smith, Muhammed R Siddiqui, Svetlana Balyasnikova, Robert I Swift, Rodrigo Perez, Angelita Habr-Gama, Gina Brown
BACKGROUND: Pathological complete response after chemoradiotherapy for rectal cancer occurs in 10% to 30% of patients. The best method to identify such patients remains unclear. Clinical assessment of residual mucosal abnormality is considered the most accurate method. In our institution, magnetic resonance tumor regression grade is performed as routine to assess response. OBJECTIVE: The purpose of this study was to compare the sensitivity of magnetic tumor regression grade against residual mucosal abnormality in detecting patients with a pathological complete response...
October 2016: Diseases of the Colon and Rectum
keyword
keyword
46646
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"